戻る Agenda
Does Sourcing Strategy Matter? Executives Debate the Influence of Outsourcing Model on Clinical Trial Execution
Session Chair(s)
Mitchell A. Katz, PHD
Vice President, Development Operations
Ferring Pharmaceuticals, United States
In this provocative session, executives from various sponsor organizations will react to the 2017 industry report on risk in clinical trials. They will share its 2017 industry findings on the state of clinical outsourcing, risk assessment, and risk-based approaches to managing quality and oversight in the context of a changing regulatory landscape. With a near equal balance of respondents identifying as using primarily FSP or primarily Full-Service models, they will shed light on what the data says about the impact of sourcing model on quality, relationships, and risk-based approaches.Forward-thinking executive leaders from pharma and CRO respondents will respond to the findings with their own interpretations, describe strategies where threats and opportunities may be addressed, and promote their own unique view.
Learning Objective : Assess the impact of clinical outsourcing model on quality, relationships, and risk-based approaches; Describe strategies addressing threats and opportunities in the changing regulatory landscape.
Speaker(s)
Panelist
David M. Johnston, PHD
PPD , United States
Executive Vice President, Clinical Development
Panelist
John Oidtman
EMD Serono, Inc., United States
COO of R&D and Senior Vice President, Strategic Business and Development Ops
Panelist
Jeremy G. Chadwick
Shire, United States
Group Vice President, Clinical Development Operations